To the Editor, {#s1a}
==============

We read "Investigation of *MDM2* oncogene copy number alterations in cases of chronic lymphocytic leukemia" (CLL) with great interest \[[@ref1]\]. Darbaş et al. \[[@ref1]\] stated: "In previous studies, *MDM2* overexpression was examined at mRNA and protein levels, but amplification of the *MDM2* gene at DNA level in CLL patients has been examined for the first time in our study" \[[@ref1]\]. Indeed, *MDM2* overexpression is an important pathological phenomenon seen in CLL \[[@ref2]\]. The investigation of *MDM2* overexpression can be useful in the diagnostic and therapeutic management of the patient. Nevertheless, we would like to point out that the present report by Darbaş et al. \[[@ref1]\] is not the first report studying amplification of the *MDM2* gene at DNA level in CLL patients. A previous report by Watanabe et al. \[[@ref3]\] already investigated this issue, although in those case the results were negative.
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Reply from the Authors

To the Editor, {#s2a}
==============

We would like to thank the authors for showing interest in our letter, which was titled "Investigation of *MDM2* oncogene copy number alterations in cases of chronic lymphocytic leukemia" \[[@ref1-1]\]. The authors have shown two previously published articles related to overexpression of *MDM2* in CLL patients. One of them was written by Watanabe et al. \[[@ref2-2]\]; they performed Southern blot analysis to examine whether *MDM2* was amplified in 23 B-CLL specimens and found that none of the patients showed amplification. In the other study, Bixby et al. \[[@ref3-3]\] reported that they had found three copies of the *MDM2* gene in 37 of 178 CLL patients using 50K SNP-array technology. After screening the literature in detail, we found two additional studies. Bueso-Ramos et al. \[[@ref4-4]\] reported 5 CLL patients not showing amplification using the Southern blot method and Huang et al. \[[@ref5-5]\] reported 4 of 11 patients with CLL showing amplification of the *MDM2* gene using the Southern blot technique. Considering these four studies, amplification of the *MDM2* gene at DNA level in CLL patients had been previously examined by Southern blot and array techniques, but we used the FISH technique in our study to demonstrate *MDM2* amplification in CLL patients.
